Related Experiment Video
Updated: Jun 30, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer
Jinping Zhang1,2,3, Shuman Zhang1, Isabella Dörflein1
1Department of Surgery, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Abstract:
Pancreatic cancer is among the cancers with the highest mortality rates. Most of the patients are found to have advanced cancer, losing the chance of surgical treatment, and there is an urgent need to find new treatment methods. Targeted therapy for specific genes that play a key role in cancer is now an important means to improve the survival rate of patients. We determined that CD73 is highly expressed in pancreatic cancer by flow cytometry and qRT-PCR assays combined with bioinformatics techniques. Application of CRISPR/Cas9 technology to knockout CD73 in human and murine cell lines, respectively, revealed that CD73 inactivation inhibited cell growth and migration and induced G1 cell cycle arrest. We also found that CD73 deletion inhibited the ERK/STAT3 pathway and activated the E-cadherin pathway. In addition, a CRISPR/Cas9 protein kinase library screen was performed and identified Pbk, Fastk, Cdk19, Adck5, Trim28, and Pfkp as possible genes regulating CD73.
Insights
Targeting CD73, a highly expressed protein in pancreatic cancer, shows promise. Inhibiting CD73 with CRISPR/Cas9 halts cancer growth and migration, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic cancer has high mortality rates, often diagnosed at advanced stages.
- Effective treatments are limited, necessitating novel therapeutic strategies.
- Targeted gene therapy is crucial for improving patient survival rates.
Purpose of the Study:
- To investigate the role of CD73 in pancreatic cancer.
- To evaluate the therapeutic potential of targeting CD73.
Main Methods:
- Utilized flow cytometry, qRT-PCR, and bioinformatics to assess CD73 expression.
- Employed CRISPR/Cas9 gene editing to knockout CD73 in pancreatic cancer cell lines.
- Performed a CRISPR/Cas9 protein kinase library screen to identify regulatory genes.
Main Results:
- CD73 was found to be highly expressed in pancreatic cancer.
- CD73 knockout inhibited cell proliferation and migration, inducing G1 cell cycle arrest.
- CD73 deletion modulated the ERK/STAT3 and E-cadherin signaling pathways.
- Identified potential CD73-regulating genes including Pbk, Fastk, Cdk19, Adck5, Trim28, and Pfkp.
Conclusions:
- CD73 is a potential therapeutic target for pancreatic cancer.
- Inhibition of CD73 demonstrates anti-cancer effects by impacting cell cycle and signaling pathways.
- Further research into CD73 and its regulators may lead to novel pancreatic cancer treatments.
Related Concept Videos
01:59CRISPR
01:28CRISPR/Cas9 Genome Editing